{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:37:18Z","timestamp":1791301038661,"version":"4.1.0"},"reference-count":119,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T00:00:00Z","timestamp":1251763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice &amp; Research Clinical Haematology"],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.1016\/j.beha.2009.09.008","type":"journal-article","created":{"date-parts":[[2009,12,2]],"date-time":"2009-12-02T10:19:00Z","timestamp":1259749140000},"page":"455-474","source":"Crossref","is-referenced-by-count":61,"title":["CML in pregnancy and childhood"],"prefix":"10.1016","volume":"22","author":[{"given":"Jane","family":"Apperley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.beha.2009.09.008_bib1","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1200\/JCO.2008.21.1839","article-title":"Ovarian failure and reproductive outcomes after childhood cancer treatment: results from the Childhood Cancer Survivor Study","volume":"27","author":"Green","year":"2009","journal-title":"J Clin Oncol"},{"issue":"9278","key":"10.1016\/j.beha.2009.09.008_bib2","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0140-6736(01)05482-4","article-title":"Pregnancy outcomes after peripheral blood or bone marrow transplantation: a retrospective survey","volume":"358","author":"Salooja","year":"2001","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.beha.2009.09.008_bib3","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1200\/JCO.2007.15.8154","article-title":"Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis","volume":"26","author":"de Lavallade","year":"2008","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.beha.2009.09.008_bib4","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.beha.2009.09.008_bib5","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1101\/gad.8.16.1888","article-title":"Abnormal kidney development and hematological disorders in PDGF beta-receptor mutant mice","volume":"8","author":"Soriano","year":"1994","journal-title":"Genes Dev"},{"issue":"14","key":"10.1016\/j.beha.2009.09.008_bib6","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1242\/dev.124.14.2691","article-title":"The PDGF alpha receptor is required for neural crest cell development and for normal patterning of the somites","volume":"124","author":"Soriano","year":"1997","journal-title":"Development"},{"issue":"20","key":"10.1016\/j.beha.2009.09.008_bib7","doi-asserted-by":"crossref","first-page":"4769","DOI":"10.1242\/dev.00721","article-title":"Roles of PDGF in animal development","volume":"130","author":"Hoch","year":"2003","journal-title":"Development"},{"issue":"7","key":"10.1016\/j.beha.2009.09.008_bib8","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/0092-8674(91)90011-M","article-title":"Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene","volume":"65","author":"Tybulewicz","year":"1991","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.beha.2009.09.008_bib9","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1093\/humupd\/5.5.535","article-title":"Stem cell factor\/c-kit system in spermatogenesis","volume":"5","author":"Mauduit","year":"1999","journal-title":"Hum Reprod Update"},{"issue":"4","key":"10.1016\/j.beha.2009.09.008_bib10","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1365-2605.2007.00755.x","article-title":"Inhibition of tyrosine kinases PDGFR and C-Kit by imatinib mesylate interferes with postnatal testicular development in the rat","volume":"30","author":"Nurmio","year":"2007","journal-title":"Int J Androl"},{"issue":"12","key":"10.1016\/j.beha.2009.09.008_bib11","doi-asserted-by":"crossref","first-page":"6226","DOI":"10.1210\/en.2008-0349","article-title":"Platelet-derived growth factor receptor beta-subtype regulates proliferation and migration of gonocytes","volume":"149","author":"Basciani","year":"2008","journal-title":"Endocrinology"},{"issue":"4","key":"10.1016\/j.beha.2009.09.008_bib12","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.reprotox.2008.03.004","article-title":"Adult reproductive functions after early postnatal inhibition by imatinib of the two receptor tyrosine kinases, c-kit and PDGFR, in the rat testis","volume":"25","author":"Nurmio","year":"2008","journal-title":"Reprod Toxicol"},{"issue":"20","key":"10.1016\/j.beha.2009.09.008_bib13","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1056\/NEJM200411113512024","article-title":"Oligospermia in a patient receiving imatinib therapy for the hypereosinophilic syndrome","volume":"351","author":"Seshadri","year":"2004","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.beha.2009.09.008_bib14","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMc0707841","article-title":"Primary ovarian insufficiency associated with imatinib therapy","volume":"358","author":"Christopoulos","year":"2008","journal-title":"N Engl J Med"},{"issue":"2 Suppl. 3","key":"10.1016\/j.beha.2009.09.008_bib15","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1053\/shem.2003.50038","article-title":"Imatinib treatment: specific issues related to safety, fertility, and pregnancy","volume":"40","author":"Hensley","year":"2003","journal-title":"Semin Hematol"},{"issue":"7","key":"10.1016\/j.beha.2009.09.008_bib16","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1200\/JCO.2005.04.6557","article-title":"Pregnancy among patients with chronic myeloid leukemia treated with imatinib","volume":"24","author":"Ault","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.beha.2009.09.008_bib17","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/j.1365-2141.2007.06542.x","article-title":"Successful pregnancies involving men with chronic myeloid leukaemia on imatinib therapy","volume":"137","author":"Ramasamy","year":"2007","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.beha.2009.09.008_bib18","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.leukres.2007.07.022","article-title":"Male patients with chronic myeloid leukemia treated with imatinib involved in healthy pregnancies: report of five cases","volume":"32","author":"Breccia","year":"2008","journal-title":"Leuk Res"},{"issue":"11","key":"10.1016\/j.beha.2009.09.008_bib19","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1182\/blood.V112.11.3230.3230","article-title":"Pregnancy outcomes among patients with chronic myeloid leukemia treated with dasatinib","volume":"112","author":"Cortes","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.09.008_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2008.03.007","article-title":"Twin pregnancy in a patient of chronic myeloid leukemia on imatinib therapy","author":"Meera","year":"2008","journal-title":"Leuk Res"},{"key":"10.1016\/j.beha.2009.09.008_bib21","doi-asserted-by":"crossref","DOI":"10.1007\/s00404-007-0547-6","article-title":"Pregnancy complicated with chronic myelogeneous leukemia (CML) successfully treated with imatinib: a case report","author":"Buyukbayrak","year":"2008","journal-title":"Arch Gynecol Obstet"},{"issue":"12","key":"10.1016\/j.beha.2009.09.008_bib22","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1080\/10428190701658751","article-title":"Pregnancy in patients with chronic myeloid leukemia treated with imatinib","volume":"48","author":"Yilmaz","year":"2007","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1016\/j.beha.2009.09.008_bib23","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1532\/IJH97.A20610","article-title":"Pregnancies in patients with chronic myeloid leukemia in the era of imatinib","volume":"84","author":"Koh","year":"2006","journal-title":"Int J Hematol"},{"issue":"8","key":"10.1016\/j.beha.2009.09.008_bib24","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.leukres.2005.01.009","article-title":"Pregnancy under treatment of imatinib and successful labor in a patient with chronic myelogenous leukemia (CML). Outcome of discontinuation of imatinib therapy after achieving a molecular remission","volume":"29","author":"Ali","year":"2005","journal-title":"Leuk Res"},{"issue":"4","key":"10.1016\/j.beha.2009.09.008_bib25","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/jjco\/hyh038","article-title":"Successful pregnancy and delivery in a patient with chronic myelogenous leukemia (CML), and management of CML with leukapheresis during pregnancy: a case report and review of the literature","volume":"34","author":"Ali","year":"2004","journal-title":"Jpn J Clin Oncol"},{"issue":"1","key":"10.1016\/j.beha.2009.09.008_bib26","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/annonc\/mdj065","article-title":"Pregnancy on imatinib: fatal outcome with meningocele","volume":"17","author":"Choudhary","year":"2006","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.beha.2009.09.008_bib27","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1093\/annonc\/mdi398","article-title":"Pregnancy outcome of two patients treated with imatinib","volume":"16","author":"Prabhash","year":"2005","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.beha.2009.09.008_bib28","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1600-0609.2005.00420.x","article-title":"Imatinib in pregnancy","volume":"74","author":"AlKindi","year":"2005","journal-title":"Eur J Haematol"},{"issue":"6","key":"10.1016\/j.beha.2009.09.008_bib29","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1080\/10428190310001645195","article-title":"Successful outcome of pregnancy in chronic myeloid leukaemia treated with imatinib","volume":"45","author":"Heartin","year":"2004","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.beha.2009.09.008_bib30","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.3324\/haematol.10935","article-title":"Two successful pregnancies in a chronic myeloid leukemia patient treated with imatinib","volume":"92","author":"Garderet","year":"2007","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.beha.2009.09.008_bib31","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1080\/10428190500399029","article-title":"Successful outcome of pregnancy in a patient with chronic myelogenous leukemia exposed to imatinib during the first trimester","volume":"47","author":"Suppiah","year":"2006","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.beha.2009.09.008_bib32","doi-asserted-by":"crossref","first-page":"121","DOI":"10.5507\/bp.2008.019","article-title":"Successful childbirth in a patient with chronic myelogenous leukemia treated with imatinib mesylate during early pregnancy","volume":"152","author":"Skoumalova","year":"2008","journal-title":"Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub"},{"issue":"4","key":"10.1016\/j.beha.2009.09.008_bib33","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.leukres.2008.08.002","article-title":"Is imatinib safe during pregnancy?","volume":"33","author":"Dolai","year":"2009","journal-title":"Leuk Res"},{"issue":"6","key":"10.1016\/j.beha.2009.09.008_bib34","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1016\/j.leukres.2008.09.012","article-title":"Persistence of molecular remission throughout pregnancy in CML after imatinib","volume":"33","author":"Sora","year":"2009","journal-title":"Leuk Res"},{"key":"10.1016\/j.beha.2009.09.008_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2009.05.012","article-title":"Response to treatment in women with chronic myeloid leukemia during pregnancy and after delivery","author":"Klamova","year":"2009","journal-title":"Leuk Res"},{"key":"10.1016\/j.beha.2009.09.008_bib36","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2007-10-114900","article-title":"The effects of imatinib on pregnancy outcome","author":"Pye","year":"2008","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2009.09.008_bib37","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/ajmg.1320580218","article-title":"Omphalocele and gastroschisis in Europe: a survey of 3 million births 1980\u20131990. EUROCAT Working Group","volume":"58","author":"Calzolari","year":"1995","journal-title":"Am J Med Genet"},{"issue":"8","key":"10.1016\/j.beha.2009.09.008_bib38","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/S0168-9525(00)02077-1","article-title":"RTK mutations and human syndromes: when good receptors turn bad","volume":"16","author":"Robertson","year":"2000","journal-title":"Trends Genet"},{"issue":"12","key":"10.1016\/j.beha.2009.09.008_bib39","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1124\/dmd.108.022764","article-title":"Lacteal secretion, fetal and maternal tissue distribution of dasatinib in rats","volume":"36","author":"He","year":"2008","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"10.1016\/j.beha.2009.09.008_bib40","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/sj.jp.7211665","article-title":"Imatinib mesylate and metabolite concentrations in maternal blood, umbilical cord blood, placenta and breast milk","volume":"27","author":"Russell","year":"2007","journal-title":"J Perinatol"},{"issue":"2","key":"10.1016\/j.beha.2009.09.008_bib41","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s00404-008-0861-7","article-title":"Imatinib use during pregnancy and breast feeding: a case report and review of the literature","volume":"280","author":"Ali","year":"2009","journal-title":"Arch Gynecol Obstet"},{"key":"10.1016\/j.beha.2009.09.008_bib42","doi-asserted-by":"crossref","DOI":"10.1007\/s00277-009-0754-2","article-title":"Imatinib in breast milk","author":"Kronenberger","year":"2009","journal-title":"Ann Hematol"},{"issue":"5","key":"10.1016\/j.beha.2009.09.008_bib43","first-page":"337","article-title":"Antineoplastic agents and pregnancy","volume":"16","author":"Doll","year":"1989","journal-title":"Semin Oncol"},{"issue":"6","key":"10.1016\/j.beha.2009.09.008_bib44","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0890-6238(96)00135-9","article-title":"Carpal and tarsal bone development is highly sensitive to three antiproliferative teratogens in mice","volume":"10","author":"Rahman","year":"1996","journal-title":"Reprod Toxicol"},{"issue":"4","key":"10.1016\/j.beha.2009.09.008_bib45","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/j.1365-2141.1992.tb06968.x","article-title":"Pregnancy during myelosuppressive treatment for chronic myelogenous leukemia","volume":"82","author":"Delmer","year":"1992","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.beha.2009.09.008_bib46","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/0002-9378(91)90285-Y","article-title":"Use of hydroxyurea in chronic myeloid leukemia during pregnancy: a case report","volume":"165","author":"Patel","year":"1991","journal-title":"Am J Obstet Gynecol"},{"issue":"6 Pt 1","key":"10.1016\/j.beha.2009.09.008_bib47","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1016\/0002-9378(92)91590-7","article-title":"Hydroxyurea and pregnancy","volume":"166","author":"Tertian","year":"1992","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"10.1016\/j.beha.2009.09.008_bib48","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/j.1365-2141.1993.tb08672.x","article-title":"Hydroxyurea treatment for chronic myeloid leukaemia during pregnancy","volume":"85","author":"Jackson","year":"1993","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.beha.2009.09.008_bib49","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1002\/1097-0142(19871101)60:9<2177::AID-CNCR2820600911>3.0.CO;2-P","article-title":"Excretion of hydroxyurea into milk","volume":"60","author":"Sylvester","year":"1987","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.beha.2009.09.008_bib50","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1046\/j.1537-2995.1978.18178118555.x","article-title":"Management of chronic myelocytic leukemia in pregnancy by cell pheresis","volume":"18","author":"Caplan","year":"1978","journal-title":"Transfusion"},{"issue":"4","key":"10.1016\/j.beha.2009.09.008_bib51","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1177\/030089168407000412","article-title":"Chronic myelocytic leukemia in pregnancy: report of a case treated with leukapheresis","volume":"70","author":"Broccia","year":"1984","journal-title":"Tumori"},{"issue":"2","key":"10.1016\/j.beha.2009.09.008_bib52","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/ajh.2830220213","article-title":"Leukapheresis for control of chronic myelogenous leukemia during pregnancy","volume":"22","author":"Fitzgerald","year":"1986","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.beha.2009.09.008_bib53","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/ajh.2830380316","article-title":"Successful management of Ph chromosome chronic myelogenous leukemia with leukapheresis during pregnancy","volume":"38","author":"Bazarbashi","year":"1991","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.beha.2009.09.008_bib54","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1097\/00001703-199612000-00013","article-title":"Thromboembolism in pregnancy: an overview","volume":"8","author":"Girling","year":"1996","journal-title":"Curr Opin Obstet Gynecol"},{"issue":"1","key":"10.1016\/j.beha.2009.09.008_bib55","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0301-2115(98)00083-9","article-title":"Low-molecular-weight heparin combined with aspirin in pregnant women with thrombophilia and a history of preeclampsia or fetal growth restriction: a preliminary study","volume":"80","author":"Riyazi","year":"1998","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"1 Suppl.","key":"10.1016\/j.beha.2009.09.008_bib56","doi-asserted-by":"crossref","first-page":"122S","DOI":"10.1378\/chest.119.1_suppl.122S","article-title":"Use of antithrombotic agents during pregnancy","volume":"119","author":"Ginsberg","year":"2001","journal-title":"Chest"},{"issue":"7","key":"10.1016\/j.beha.2009.09.008_bib57","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1046\/j.1538-7836.2003.00307.x","article-title":"Management of venous thromboembolism during pregnancy","volume":"1","author":"Ginsberg","year":"2003","journal-title":"J Thromb Haemost"},{"issue":"4","key":"10.1016\/j.beha.2009.09.008_bib58","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/0002-9378(93)90021-A","article-title":"The effect of low-dose aspirin on fetal urine output and amniotic fluid volume","volume":"169","author":"Maher","year":"1993","journal-title":"Am J Obstet Gynecol"},{"issue":"4","key":"10.1016\/j.beha.2009.09.008_bib59","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/0002-9378(93)90025-E","article-title":"The effect of low-dose aspirin on umbilical artery Doppler measurements","volume":"169","author":"Owen","year":"1993","journal-title":"Am J Obstet Gynecol"},{"issue":"6","key":"10.1016\/j.beha.2009.09.008_bib60","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1016\/j.ajog.2004.05.001","article-title":"Interferon alfa treatment for pregnant women affected by essential thrombocythemia: case reports and a review","volume":"191","author":"Martinelli","year":"2004","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.beha.2009.09.008_bib61","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/(SICI)1520-6661(199603\/04)5:2<74::AID-MFM5>3.0.CO;2-N","article-title":"Successful treatment of essential thrombocythemia in a pregnancy with recombinant interferon-alpha 2a","volume":"5","author":"Milano","year":"1996","journal-title":"J Matern Fetal Med"},{"issue":"1","key":"10.1016\/j.beha.2009.09.008_bib62","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/ajh.2830430125","article-title":"Alpha 2b-interferon therapy and pregnancy\u2013report of a case of essential thrombocythemia","volume":"43","author":"Pardini","year":"1993","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.beha.2009.09.008_bib63","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/ajh.2830400122","article-title":"Normal pregnancy in a patient with essential thrombocythemia treated with interferon-alpha 2b","volume":"40","author":"Petit","year":"1992","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.beha.2009.09.008_bib64","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1159\/000264183","article-title":"Pharmacokinetics of interferon-alpha in pregnant women and fetoplacental passage","volume":"10","author":"Pons","year":"1995","journal-title":"Fetal Diagn Ther"},{"issue":"6","key":"10.1016\/j.beha.2009.09.008_bib65","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1080\/10428190902926973","article-title":"Previous best responses can be re-achieved by resumption after imatinib discontinuation in patients with chronic myeloid leukemia: implication for intermittent imatinib therapy","volume":"50","author":"Goh","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.beha.2009.09.008_bib66","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","article-title":"Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years","volume":"109","author":"Rousselot","year":"2007","journal-title":"Blood"},{"issue":"Suppl. 2","key":"10.1016\/j.beha.2009.09.008_bib67","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1038\/bmt.2008.282","article-title":"Innovative approaches of targeted therapy for CML of childhood in combination with paediatric haematopoietic SCT","volume":"42","author":"Suttorp","year":"2008","journal-title":"Bone Marrow Transplant"},{"issue":"18","key":"10.1016\/j.beha.2009.09.008_bib68","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1016\/j.ejca.2003.08.006","article-title":"Incidence of malignant disease by morphological type, in young persons aged 12\u201324 years in England, 1979\u20131997","volume":"39","author":"Birch","year":"2003","journal-title":"Eur J Cancer"},{"issue":"8","key":"10.1016\/j.beha.2009.09.008_bib69","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/sj.leu.2402194","article-title":"Clinicopathologic characteristics of leukemia in Japanese children and young adults","volume":"15","author":"Horibe","year":"2001","journal-title":"Leukemia"},{"issue":"2 Suppl","key":"10.1016\/j.beha.2009.09.008_bib70","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.2307\/3578893","article-title":"Cancer incidence in atomic bomb survivors. Part III. Leukemia, lymphoma and multiple myeloma, 1950\u20131987","volume":"137","author":"Preston","year":"1994","journal-title":"Radiat Res"},{"issue":"1","key":"10.1016\/j.beha.2009.09.008_bib71","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1542\/peds.2004-2473","article-title":"Clinical and biological features at diagnosis in 40 children with chronic myeloid leukemia","volume":"116","author":"Millot","year":"2005","journal-title":"Pediatrics"},{"issue":"9","key":"10.1016\/j.beha.2009.09.008_bib72","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1182\/blood.V78.9.2407.2407","article-title":"BCR-ABL rearrangements in children with Philadelphia chromosome- positive chronic myelogenous leukemia","volume":"78","author":"Aurer","year":"1991","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.beha.2009.09.008_bib73","first-page":"723","article-title":"Molecular analysis of Philadelphia-positive childhood chronic myeloid leukemia","volume":"6","author":"Fioretos","year":"1992","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.beha.2009.09.008_bib74","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.cancergencyto.2006.01.015","article-title":"Childhood CML in India: b2a2 transcript is more common than b3a2","volume":"169","author":"Hasan","year":"2006","journal-title":"Cancer Genet Cytogenet"},{"issue":"2","key":"10.1016\/j.beha.2009.09.008_bib75","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/j.1600-0609.2008.01170.x","article-title":"Correlation of BCR\/ABL transcript variants with patients' characteristics in childhood chronic myeloid leukaemia","volume":"82","author":"Adler","year":"2009","journal-title":"Eur J Haematol"},{"issue":"5","key":"10.1016\/j.beha.2009.09.008_bib76","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1182\/blood.V78.5.1155.1155","article-title":"Does the breakpoint within the major breakpoint cluster region (M-bcr) influence the duration of the chronic phase in chronic myeloid leukemia? An analytical comparison of current literature","volume":"78","author":"Mills","year":"1991","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.beha.2009.09.008_bib77","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.1182\/blood.V78.12.3125.3125","article-title":"A possible correlation between the type of bcr-abl hybrid messenger RNA and platelet count in Philadelphia-positive chronic myelogenous leukemia","volume":"78","author":"Inokuchi","year":"1991","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2009.09.008_bib78","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0959-8049(94)00449-F","article-title":"Detection by polymerase chain reaction of BCR\/ABL transcripts in myeloproliferative diseases at time of diagnosis and for monitoring chronic myelogenous leukaemia patients after bone marrow transplantation","volume":"31A","author":"Bianchi","year":"1995","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.beha.2009.09.008_bib79","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/j.1365-2141.1995.tb08362.x","article-title":"Analysis of molecular breakpoint and m-RNA transcripts in a prospective randomized trial of interferon in chronic myeloid leukaemia: no correlation with clinical features, cytogenetic response, duration of chronic phase, or survival","volume":"89","author":"Shepherd","year":"1995","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.beha.2009.09.008_bib80","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/S0959-8049(00)00128-3","article-title":"The possible influences of B2A2 and B3A2 BCR\/ABL protein structure on thrombopoiesis in chronic myeloid leukaemia","volume":"36","author":"Perego","year":"2000","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.beha.2009.09.008_bib81","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1046\/j.1365-2257.2002.00413.x","article-title":"BCR\/ABL p210, p190 and p230 fusion genes in 250 Mexican patients with chronic myeloid leukaemia (CML)","volume":"24","author":"Arana-Trejo","year":"2002","journal-title":"Clin Lab Haematol"},{"issue":"6","key":"10.1016\/j.beha.2009.09.008_bib82","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1111\/j.1365-2141.2005.05731.x","article-title":"Long-term follow-up of Philadelphia chromosome-positive (Ph) chronic myeloid leukaemia (CML) in children and adolescents managed at a single institution over a 20-year period","volume":"130","author":"Giona","year":"2005","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.beha.2009.09.008_bib83","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0950-3536(97)80009-1","article-title":"Interferon-alpha: results from randomized trials","volume":"10","author":"Richards","year":"1997","journal-title":"Baillieres Clin Haematol"},{"issue":"8","key":"10.1016\/j.beha.2009.09.008_bib84","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1002\/1097-0142(19911015)68:8<1678::AID-CNCR2820680803>3.0.CO;2-J","article-title":"Response to alpha-interferon in children with Philadelphia chromosome-positive chronic myelocytic leukemia","volume":"68","author":"Dow","year":"1991","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.beha.2009.09.008_bib85","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1002\/pbc.20586","article-title":"Results of a phase II trial testing interferon-alpha 2b and cytarabine in children and adolescents with chronic myelogenous leukemia","volume":"47","author":"Millot","year":"2006","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"10.1016\/j.beha.2009.09.008_bib86","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1182\/blood.V99.6.1971","article-title":"Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation","volume":"99","author":"Weisdorf","year":"2002","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2009.09.008_bib87","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1182\/blood-2002-12-3637","article-title":"Stem cell transplantation for chronic myeloid leukemia in children","volume":"102","author":"Cwynarski","year":"2003","journal-title":"Blood"},{"issue":"9134","key":"10.1016\/j.beha.2009.09.008_bib88","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S0140-6736(98)03030-X","article-title":"Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation","volume":"352","author":"Gratwohl","year":"1998","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.beha.2009.09.008_bib89","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1055\/s-2008-1046479","volume":"208","author":"Creutzig","year":"1996","journal-title":"Klin Padiatr"},{"issue":"10","key":"10.1016\/j.beha.2009.09.008_bib90","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/sj.bmt.1704255","article-title":"Allogeneic bone marrow transplantation for chronic myeloid leukemia in childhood: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC)","volume":"32","author":"Millot","year":"2003","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.beha.2009.09.008_bib91","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/sj.bmt.1705240","article-title":"Reduced intensity conditioning using intravenous busulfan, fludarabine and rabbit ATG for children with nonmalignant disorders and CML","volume":"37","author":"Horn","year":"2006","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.beha.2009.09.008_bib92","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.bbmt.2005.04.002","article-title":"Reduced-intensity allogeneic stem cell transplantation in adults and children with malignant and nonmalignant diseases: end of the beginning and future challenges","volume":"11","author":"Satwani","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"10.1016\/j.beha.2009.09.008_bib93","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1182\/blood-2004-09-3544","article-title":"Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT","volume":"106","author":"Crawley","year":"2005","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.beha.2009.09.008_bib94","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1182\/blood-2005-08-3320","article-title":"Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy","volume":"107","author":"Kaeda","year":"2006","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beha.2009.09.008_bib95","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1182\/blood.V96.8.2712","article-title":"Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia","volume":"96","author":"Dazzi","year":"2000","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.beha.2009.09.008_bib96","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1038\/sj.leu.2403068","article-title":"Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia","volume":"17","author":"Olavarria","year":"2003","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.beha.2009.09.008_bib97","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/bmt.2008.135","article-title":"Donor leukocyte infusions to treat hematologic malignancy relapse following allo-SCT in a pediatric population","volume":"42","author":"Levine","year":"2008","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"10.1016\/j.beha.2009.09.008_bib98","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1182\/blood.V112.11.332.332","article-title":"Prediction of cytogenetic response to second generation TKI therapy in CML chronic phase patients who have failed imatinib therapy and early identification of factors that influence survival","volume":"112","author":"Milojkovic","year":"2008","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.beha.2009.09.008_bib99","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1182\/blood-2003-09-3032","article-title":"Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study","volume":"104","author":"Champagne","year":"2004","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.beha.2009.09.008_bib100","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa051140","article-title":"Altered bone and mineral metabolism in patients receiving imatinib mesylate","volume":"354","author":"Berman","year":"2006","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.beha.2009.09.008_bib101","doi-asserted-by":"crossref","first-page":"4334","DOI":"10.1182\/blood-2005-09-3568","article-title":"Imatinib as a potential antiresorptive therapy for bone disease","volume":"107","author":"Dewar","year":"2006","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.beha.2009.09.008_bib102","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1182\/blood-2007-07-104281","article-title":"Long-term imatinib therapy promotes bone formation in CML patients","volume":"111","author":"Fitter","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.09.008_bib103","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1200\/jco.2008.26.15_suppl.3591","article-title":"Pediatric phase I trial and pharmacokinetic (PK) study of dasatinib: a report from the Children's Oncology Group Phase I consortium","volume":"26","author":"Aplenc","year":"2008","journal-title":"Journal of Clinical Oncology"},{"issue":"11","key":"10.1016\/j.beha.2009.09.008_bib104","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1182\/blood.V112.11.3241.3241","article-title":"Dasatinib in children and adolescents with relapsed or refractory leukemia: interim results of the CA180-018 phase i study from the ITCC Consortium","volume":"112","author":"Zwaan","year":"2008","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.beha.2009.09.008_bib105","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia","volume":"349","author":"Hughes","year":"2003","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.beha.2009.09.008_bib106","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1182\/blood-2004-07-2528","article-title":"Final adult height of patients who received hematopoietic cell transplantation in childhood","volume":"105","author":"Sanders","year":"2005","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.beha.2009.09.008_bib107","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1182\/blood.V98.13.3569","article-title":"Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies","volume":"98","author":"Socie","year":"2001","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2009.09.008_bib108","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1182\/blood-2004-03-1010","article-title":"Late effects in survivors of chronic myeloid leukemia treated with hematopoietic cell transplantation: results from the Bone Marrow Transplant Survivor Study","volume":"104","author":"Baker","year":"2004","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beha.2009.09.008_bib109","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1001\/archpedi.159.8.706","article-title":"Performance limitations and participation restrictions among childhood cancer survivors treated with hematopoietic stem cell transplantation: the bone marrow transplant survivor study","volume":"159","author":"Ness","year":"2005","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"6","key":"10.1016\/j.beha.2009.09.008_bib110","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1002\/cncr.21752","article-title":"Visual, auditory, sensory, and motor impairments in long-term survivors of hematopoietic stem cell transplantation performed in childhood: results from the Bone Marrow Transplant Survivor study","volume":"106","author":"Gurney","year":"2006","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.beha.2009.09.008_bib111","first-page":"1145","article-title":"Imatinib preceding allogeneic stem cell transplantation in chronic myeloid leukemia","volume":"91","author":"Perz","year":"2006","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.beha.2009.09.008_bib112","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1182\/blood-2006-06-031682","article-title":"The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia","volume":"109","author":"Oehler","year":"2007","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2009.09.008_bib113","first-page":"452","article-title":"The effect of prior exposure to imatinib on transplant-related mortality","volume":"91","author":"Deininger","year":"2006","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.beha.2009.09.008_bib114","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1182\/blood-2008-02-141689","article-title":"Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia","volume":"112","author":"Lee","year":"2008","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2009.09.008_bib115","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.09.008_bib116","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2008-06-162388","article-title":"European LeukemiaNet criteria for failure or sub-optimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor","author":"Marin","year":"2008","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2009.09.008_bib117","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1182\/blood-2006-09-047266","article-title":"Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy","volume":"109","author":"Hochhaus","year":"2007","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.beha.2009.09.008_bib118","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","article-title":"Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance","volume":"110","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2009.09.008_bib119","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1182\/blood-2008-02-141580","article-title":"Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia","volume":"112","author":"Tam","year":"2008","journal-title":"Blood"}],"container-title":["Best Practice &amp; Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152169260900070X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152169260900070X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T06:05:57Z","timestamp":1634277957000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152169260900070X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9]]},"references-count":119,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["S152169260900070X"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2009.09.008","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2009,9]]}}}